NeuBase Therapeutics Inc
F:O7PA
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (13.3), the stock would be worth €-0.23 (247% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -9 | €0.16 |
0%
|
| Industry Average | 13.3 | €-0.23 |
-247%
|
| Country Average | 14.4 | €-0.25 |
-259%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
N
|
NeuBase Therapeutics Inc
F:O7PA
|
107.5m EUR | -9 | -9.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 171.3 | -159 901.4 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
392.5B USD | 16.3 | 167.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.8B USD | 14.7 | 25.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
190.5B USD | 15.9 | 23.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.2B USD | 23.6 | 32.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581.8 | -534.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.3B USD | 13.8 | 18.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
74.1B AUD | 11.8 | 17.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR | 57.4 | 33.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.7 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
NeuBase Therapeutics Inc
Glance View
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.
